Navigation Links
Cambrex Reports Second Quarter 2014 Financial Results
Date:8/1/2014

and Chief Executive Officer in this document.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2013, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, changes in foreign exchange rates, uncollectible receivables, the timing of orders, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products and continued demand in the U.S. for late stage clinical products or the successful outcome of the Company's investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on t
'/>"/>

SOURCE Cambrex Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Cambrex Manufacturing Facility Completes Successful US FDA Inspection
2. Cambrex to Present at Oppenheimer 24th Annual Healthcare Conference
3. Cambrex To Present At UBS Global Healthcare Conference
4. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
5. Cambrex Reports Second Quarter 2012 Results
6. Cambrex to Announce Fourth Quarter 2011 Financial Results on February 6, 2012
7. Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com
8. United Therapeutics Corporation Reports Second Quarter 2014 Financial Results
9. Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com
10. Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz
11. Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... 2015 Cirrascale Corporation ®, ... rackmount computing and storage infrastructure for conventional and ... its high density scale-out, two-in-one video delivery and ... . The high density, two-in-one system supports the ... with Intel® Iris™ Pro graphics P6300 and provides ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 “Stem Cell Therapy ... more mainstream, and it is used often as an adjunct ... general practitioners are not yet aware or comfortable enough with ... therapy is most often reserved for the last resort cases ... pet can barely lift a paw to get around. It ...
(Date:6/2/2015)... 2, 2015   Sigma-Aldrich Corporation (NASDAQ: ... company, announced today it has entered into an ... genetically engineered human neural differentiated cells and accompanying ... neurological diseases. These new products, in combination with ... tools for the study of central nervous system ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 2Sigma-Aldrich to Launch XCell Science Genetically Engineered iPSC-Derived Neural Disease Cells 3
... The Wisconsin Department of Commerce has announced ... Wisconsin businesses for technology development projects. , ,NovaScan, a ... of materials used to identify different tissue types, will ... develop and test a prototype for clinical application of ...
... adison, Wis. - So you want to ... business! Where do you begin? , ,The idea usually comes ... an employee, or forming a business entity, protecting this commercial ... , ,But what type of intellectual property is this? ...
... the Health Insurance Portability and Accountability Act (HIPAA) ... can understand that since I am a practicing dentist with ... at stake. I am what they call a "stakeholder" in ... , ,More important than my job, I am a ...
Cached Biology Technology:Starting a tech business? Step 1 is minding the intellectual property 2Starting a tech business? Step 1 is minding the intellectual property 3Careful with that electronic health record, Mr. Leavitt 2Careful with that electronic health record, Mr. Leavitt 3Careful with that electronic health record, Mr. Leavitt 4
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... Conn. , May 5, 2015, NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, reminds ... Company,s Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS ... May 5-7, 2015. The three-day conference is ... David is speaking in is themed Global Fraud: Where ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... in understanding how plants pass signals of stress due ... nucleus. They know that chloroplasts ?the cellular organelles that ... different signals that can indicate a plant is under ... facing over the coming decades through global warming, this ...
... Gore's film, An Inconvenient Truth, has generated greater awareness ... more rapid warming that has occurred within major cities. ... degrees hotter than their surroundings. These metropolitan hot spots, ... stress the animals and plants that make their home ...
... international group of scientists has announced a major ... the activities of genes in living organisms. ... to describe the complex events that occur when ... Understanding these events is crucial for developing new ...
Cached Biology News:Discovery of 'master switch' for the communication process between chloroplast and nuclei of plants 2Discovery of 'master switch' for the communication process between chloroplast and nuclei of plants 3City ants take the heat 2Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Request Info...
... Clone/PAD: 5B15-5B-11E. Immunogen: Synthetic peptide derived ... MUC5B protein. Specificity: Specific for ... On Western blots it identifies the target ... Human (positive controls: deglycosylated secreted media from ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Biology Products: